Ophthalmologic Manifestations of Primary Sjögren’s Syndrome
Abstract
:1. Introduction
1.1. Signs and Symptoms
1.2. Diagnosis
2. Pathogenetic Mechanisms
2.1. Innate Immunity
2.2. Adaptive Immune System
2.3. Genetics
2.4. Hormonal Influences
3. Ocular Surface Unit Involvement
3.1. Lacrimal Gland
3.2. Keratoconjunctival Involvement
3.3. Meibomian Glands
4. Therapy
4.1. Topical Therapy
4.2. Systemic Therapy
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Mathews, P.M.; Robinson, S.A.; Gire, A.; Baer, A.N.; Akpek, E.K. Extraglandular ocular involvement and morbidity and mortality in primary Sjögren’s syndrome. PLoS ONE 2020, 15, e0239769. [Google Scholar] [CrossRef]
- Tashbayev, B.; Rusthen, S.; Young, A.; Herlofson, B.B.; Hove, L.H.; Singh, P.B.; Rykke, M.; Aqrawi, L.A.; Chen, X.; Utheim, Ø.A. Interdisciplinary, comprehensive oral and ocular evaluation of patients with primary Sjögren’s syndrome. Sci. Rep. 2017, 7, 10761. [Google Scholar] [CrossRef]
- Franceschini, F.; Cavazzana, I.; Andreoli, L.; Tincani, A. The 2016 classification criteria for primary Sjogren’s syndrome: What’s new? BMC Med. 2017, 15, 69. [Google Scholar] [CrossRef] [Green Version]
- Hayashi, T. Dysfunction of lacrimal and salivary glands in Sjögren’s syndrome: Nonimmunologic injury in preinflammatory phase and mouse model. J. Biomed. Biotechnol. 2011, 2011, 407031. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Both, T.; Dalm, V.A.; van Hagen, P.M.; van Daele, P.L. Reviewing primary Sjögren’s syndrome: Beyond the dryness—From pathophysiology to diagnosis and treatment. Int. J. Med. Sci. 2017, 14, 191–200. [Google Scholar] [CrossRef] [Green Version]
- Del Papa, N.; Vitali, C. Management of primary Sjögren’s syndrome: Recent developments and new classification criteria. Ther. Adv. Musculoskelet. Dis. 2018, 10, 39–54. [Google Scholar] [CrossRef] [Green Version]
- Thomas, E.; Hay, E.M.; Hajeer, A.; Silman, A.J. Sjögren’s syndrome: A community-based study of prevalence and impact. Br. J. Rheumatol. 1998, 37, 1069–1076. [Google Scholar] [CrossRef] [Green Version]
- Patel, R.; Shahane, A. The epidemiology of Sjögren’s syndrome. Clin Epidemiol. 2014, 6, 247–255. [Google Scholar] [PubMed] [Green Version]
- Jacobson, D.L.; Gange, S.J.; Rose, N.R.; Graham, N.M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 1997, 84, 223–243. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Helmick, C.G.; Felson, D.T.; Lawrence, R.C.; Gabriel, S.; Hirsch, R.; Kwoh, C.K.; Liang, M.H.; Kremers, H.M.; Mayes, M.D.; Merkel, P.A.; et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008, 58, 15–25. [Google Scholar] [CrossRef]
- Bron, A.J.; de Paiva, C.S.; Chauhan, S.K.; Bonini, S.; Gabison, E.; Jain, S.; Knop, E.; Markoulli, M.; Ogawa, Y.; Pérez, V.; et al. TFOS DEWS II pathophysiology report. Ocular Surf. 2017, 15, 438–510. [Google Scholar] [CrossRef]
- Aqrawi, L.A.; Chen, X.; Jensen, J.L.; Morthen, M.K.; Thiede, B.; Utheim, Ø.A.; Palm, Ø.; Tashbayev, B.; Utheim, T.P.; Galtung, H.K. Severity of clinical dry eye manifestations influences protein expression in tear fluid of patients with primary Sjögren’s syndrome. PLoS ONE 2018, 13, e0205762. [Google Scholar] [CrossRef] [PubMed]
- Rasmussen, A.; Stone, D.U.; Kaufman, C.E.; Hefner, K.S.; Fram, N.R.; Siatkowski, R.L.; Huang, A.J.W.; Chodosh, J.; Rasmussen, P.T.; Fife, D.A.; et al. Reproducibility of ocular surface staining in the assessment of Sjögren syndrome-related keratoconjunctivitis sicca: Implications on disease classification. ACR Open Rheumatol. 2019, 1, 292–302. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stefanski, A.L.; Tomiak, C.; Pleyer, U.; Dietrich, T.; Burmester, G.R.; Dörner, T. The diagnosis and treatment of Sjögren’s syndrome. Deutsches Arzteblatt Int. 2017, 114, 354–361. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baer, A.N.; Walitt, B. Update on Sjögren syndrome and other causes of sicca in older adults. Rheum. Dis. Clin. North Am. 2018, 44, 419–436. [Google Scholar] [CrossRef]
- Acs, M.; Caffery, B.; Barnett, M.; Edmonds, C.; Johnson-Tong, L.; Maharaj, R.; Pemberton, B.; Papinski, D.; Harthan, J.; Srinivasan, S. Customary practices in the monitoring of dry eye disease in Sjogren’s syndrome. J. Optom. 2018, 11, 232–241. [Google Scholar] [CrossRef]
- Akpek, E.K.; Bunya, V.Y.; Saldanha, I.J. Sjögren’s syndrome: More than just dry eye. Cornea 2019, 38, 658–661. [Google Scholar] [CrossRef] [PubMed]
- Billings, M.; Dye, B.A.; Iafolla, T.; Baer, A.N.; Grisius, M.; Alevizos, I. Significance and implications of patient-reported xerostomia in Sjögren’s syndrome: Findings from the National Institutes of Health Cohort. EBioMedicine 2016, 12, 270–279. [Google Scholar] [CrossRef] [Green Version]
- De Sousa Gomes, P.; Juodzbalys, G.; Fernandes, M.H.; Guobis, Z. Diagnostic approaches to Sjögren’s syndrome: A literature review and own clinical experience. J. Oral Maxillofac. Res. 2012, 3, e3. [Google Scholar]
- Zeron, P.B.; Retamozo, S.; Bové, A.; Kostov, B.A.; Sisó, A.; Ramos-Casals, M. Diagnosis of liver involvement in primary Sjögren syndrome. J. Clin. Transl. Hepatol. 2013, 1, 94–102. [Google Scholar]
- Ienopoli, S.; Carsons, S.E. Extraglandular manifestations of primary Sjögren’s syndrome. Oral Maxillofac. Surg. Clin. North Am. 2014, 26, 91–99. [Google Scholar] [CrossRef] [PubMed]
- Jonsson, R.; Brokstad, K.A.; Jonsson, M.V.; Delaleu, N.; Skarstein, K. Current concepts on Sjögren’s syndrome—Classification criteria and biomarkers. Eur. J. Oral Sci. 2018, 126, 37–48. [Google Scholar] [CrossRef] [PubMed]
- Bowman, S.J.; Fox, R.I. Classification criteria for Sjogren’s syndrome: Nothing ever stands still! Ann. Rheum. Dis. 2014, 73, 1–2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shiboski, C.H.; Shiboski, S.C.; Seror, R.; Criswell, L.A.; Labetoulle, M.; Lietman, T.M.; Rasmussen, A.; Scofield, H.; Vitali, C.; Bowmna, S.J.; et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann. Rheum. Dis. 2017, 76, 9. [Google Scholar] [CrossRef] [PubMed]
- Chen, W.; Cao, H.; Lin, J.; Olsen, N.; Zheng, S.G. Biomarkers for primary Sjogren’s syndrome. Genom. Proteom. Bioinform. 2015, 13, 219–223. [Google Scholar] [CrossRef] [Green Version]
- Hamm-Alvarez, S.F.; Janga, S.R.; Edman, M.C.; Madrigal, S.; Shah, M.; Frousiakis, S.E.; Renduchintala, K.; Zhu, J.; Bricel, S.; Silka, K.; et al. Tear cathepsin S as a candidate biomarker for Sjogren’s syndrome. Arthritis Rheumatol. 2014, 66, 1872–1881. [Google Scholar] [CrossRef] [Green Version]
- Rose, T.; Szelinski, F.; Lisney, A.; Reiter, K.; Fleischer, S.J.; Burmester, G.R.; Radbruch, A.; Hiepe, F.; Grützkau, A.; Biesen, R.; et al. SIGLEC1 is a biomarker of dis- ease activity and indicates extraglandular manifestation in primary Sjögren’s syndrome. RMD Open 2016, 2, e000292. [Google Scholar] [CrossRef] [Green Version]
- Pauley, K.M.; Stewart, C.M.; Gauna, A.E.; Dupre, L.C.; Kuklani, R.; Chan, A.L.; Pauley, B.A.; Reeves, W.H.; Chan, E.K.; Cha, S. Altered miR-146a expression in Sjogren’s syndrome and its functional role in innate immunity. Eur. J. Immunol. 2011, 41, 2029–2039. [Google Scholar] [CrossRef] [Green Version]
- Tobon, G.J.; Saraux, A.; Gottenberg, J.E.; Quartuccio, L.; Fabris, M.; Seror, R.; Devauchelle-Pensec, V.; Morel, J.; Rist, S.; Mariette, X.; et al. Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjogren’s syndrome. Arthritis Rheum. 2013, 65, 3218–3227. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gottenberg, J.E.; Seror, R.; Miceli-Richard, C.; Benessiano, J.; Devauchelle-Pensec, V.; Dieude, P.; Dubost, J.-J.; Fauchais, L.-L.; Goeb, V.; Hachulla, E.; et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren’s syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS ONE 2013, 8, e59868. [Google Scholar] [CrossRef] [Green Version]
- Brkic, Z.; Versnel, M.A. Type I IFN signature in primary Sjogren’s syndrome patients. Expert Rev. Clin. Immunol. 2014, 10, 457–467. [Google Scholar] [CrossRef]
- Brkic, Z.; Maria, N.I.; van Helden-Meeuwsen, C.G.; van de Merwe, J.P.; van Daele, P.L.; Dalm, V.A.; Wildenberg, M.E.; Beumer, W.; Drexhage, H.A.; Versnel, M.A. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren’s syndrome and association with disease activity and BAFF gene expression. Ann. Rheum. Dis. 2013, 72, 728–735. [Google Scholar] [CrossRef] [Green Version]
- Emamian, E.S.; Leon, J.M.; Lessard, C.J.; Grandits, M.; Baechler, E.C.; Gaffney, P.M.; Segal, B.; Rhodus, N.L.; Moser, K.L. Peripheral blood gene expression profiling in Sjogren’s syndrome. Genes Immun. 2009, 10, 285–296. [Google Scholar] [CrossRef] [PubMed]
- Reale, M.; D’Angelo, C.; Costantini, E.; Laus, M.; Moretti, A.; Croce, A. MicroRNA in Sjogren’s syndrome: Their potential roles in pathogenesis and diagnosis. J. Immunol. Res. 2018, 2018, 7510174. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alevizos, I.; Alexander, S.; Turner, R.J.; Illei, G.G. MicroRNA expression profiles as biomarkers of minor salivary gland inflam-mation and dysfunction in Sjogren’s syndrome. Arthritis Rheum. 2011, 63, 535–544. [Google Scholar] [CrossRef] [Green Version]
- Zhou, M.; Song, S.; Wu, S.; Duan, T.; Chen, L.; Ye, J.; Xiao, J. Diagnostic accuracy of salivary gland ultrasonography with different scoring systems in Sjögren’s syndrome: A systematic review and meta-analysis. Sci Rep. 2018, 8, 17128. [Google Scholar] [CrossRef]
- Cornec, D.; Jousse-Joulin, S.; Pers, J.O.; Marhadour, T.; Cochener, B.; Boisramé-Gastrin, S.; Nowak, E.; Youinou, P.; Saraux, A.; Devauchelle-Pensec, V. Contribution of salivary gland ultrasonography to the diagnosis of Sjögren’s syndrome: Toward new diagnostic criteria? Arthritis Rheum. 2013, 65, 216–225. [Google Scholar] [CrossRef]
- Song, G.G.; Lee, Y.H. Diagnostic accuracies of sialography and salivary ultrasonography in Sjogren’s syndrome patients: A meta- analysis. Clin. Exp. Rheumatol. 2014, 32, 516–522. [Google Scholar] [PubMed]
- Nocturne, G.; Mariette, X. Advances in understanding the pathogenesis of primary Sjogren’s syndrome. Nat. Rev. Rheumatol. 2013, 9, 544e56. [Google Scholar] [CrossRef]
- Triantafyllopoulou, A.; Moutsopoulos, H.M. Autoimmunity and coxsackievirus infection in primary Sjogren’s syndrome. Ann. NY Acad. Sci. 2005, 1050, 389e96. [Google Scholar] [CrossRef] [PubMed]
- Casciola-Rosen, L.; Andrade, F.; Ulanet, D.; Wong, W.B.; Rosen, A. Cleavage by granzyme B is strongly predictive of autoantigen status: Implications for initiation of autoimmunity. J. Exp. Med. 1999, 190, 815e26. [Google Scholar] [CrossRef]
- Cornec, D.; Devauchelle-Pensec, V.; Tobon, G.J.; Pers, J.O.; Jousse-Joulin, S.; Saraux, A. B cells in Sjogren’s syndrome: From pathophysiology to diagnosis and treatment. J. Autoimmun. 2012, 39, 161e7. [Google Scholar] [CrossRef]
- Nandula, S.R.; Scindia, Y.M.; Dey, P.; Bagavant, H.; Deshmukh, U.S. Activation of innate immunity accelerates sialoadenitis in a mouse model for Sjögren’s syndrome-like disease. Oral Dis. 2011, 17, 801–807. [Google Scholar] [CrossRef] [PubMed]
- Kapsogeorgou, E.K.; Abu-Helu, R.F.; Moutsopoulos, H.M.; Manoussakis, M.N. Salivary gland epithelial cell exosomes: A source of autoantigenic ribonucleoproteins. Arthritis Rheum. 2005, 52, 1517e21. [Google Scholar] [CrossRef]
- Thompson, N.; Isenberg, D.A.; Jury, E.C.; Ciurtin, C. Exploring BAFF: Its expression, receptors and contribution to the immunopathogenesis of Sjögren’s syndrome. Rheumatology 2016, 55, 1548–1555. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Boehm, N.; Riechardt, A.I.; Wiegand, M.; Pfeiffer, N.; Grus, F.H. Proinflammatory cytokine profiling of tears from dry eye patients by means of antibody microarrays. Investig. Ophthalmol. Vis. Sci. 2011, 52, 7725e30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rahimy, E.; Pitcher, J.D., 3rd; Pangelinan, S.B.; Chen, W.; Farley, W.J.; Niederkorn, J.Y.; Stern, M.E.; Li, D.-Q.; Pflugfelder, S.C.; De Paiva, C.S. Spontaneous autoimmune dacryoadenitis in aged CD25KO mice. Am. J. Pathol. 2010, 177, 744e53. [Google Scholar]
- Cha, S.; Brayer, J.; Gao, J.; Brown, V.; Killedar, S.; Yasunari, U.; Peck, A.B. A dual role for interferon-γ in the pathogenesis of Sjogren’s syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse. Scand. J. Immunol. 2004, 60, 552–565. [Google Scholar] [CrossRef] [PubMed]
- Kang, E.H.; Lee, Y.J.; Hyon, J.Y.; Yun, P.Y.; Song, Y.W. Salivary cytokine profiles in primary Sjogren’s syndrome differ from those in non-Sjogren sicca in terms of TNF-α levels and Th-1/Th-2 ratios. Clin. Exp. Rheumatol. 2011, 29, 970e6. [Google Scholar]
- Qi, J.; Li, D.; Shi, G.; Zhang, X.; Pan, Y.; Dou, H.; Wang, T.; Yao, G.; Hou, Y. Interleukin-12 exacerbates Sjögren’s syndrome through induction of myeloid-derived suppressor cells. Mol. Med. Rep. 2019, 20, 1131–1138. [Google Scholar] [PubMed] [Green Version]
- McGrath-Morrow, S.; Laube, B.; Tzou, S.C.; Cho, C.; Cleary, J.; Kimura, H.; Rose, N.R.; Caturegli, P. IL-12 overexpression in mice as a model for Sjögren lung disease. Am. J. Physiol. Lung Cell Mol. Physiol. 2006, 291, L837–L846. [Google Scholar] [CrossRef] [Green Version]
- Vosters, J.L.; Landek-Salgado, M.A.; Yin, H.; Swaim, W.D.; Kimura, H.; Tak, P.P.; Caturegli, P.; Chiorini, J.A. Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjögren’s syndrome. Arthritis Rheum. 2009, 60, 3633–3641. [Google Scholar] [CrossRef] [Green Version]
- Verstappen, G.M.; Corneth, O.B.J.; Bootsma, H.; Kroese, F.G.M. Th17 cells in primary Sjögren’s syndrome: Pathogenicity and plasticity. J. Autoimmun. 2018, 87, 16–25. [Google Scholar] [CrossRef] [PubMed]
- Woyciechowski, S.; Weißert, K.; Ammann, S.; Aichele, P.; Pircher, H. NK1.1+ innate lymphoid cells in salivary glands inhibit establishment of tissue-resident memory CD8+ T cells in mice. Eur. J. Immunol. 2020, 50, 1952–1958. [Google Scholar] [CrossRef]
- Cortez, V.S.; Cervantes-Barragan, L.; Robinette, M.L.; Bando, J.K.; Wang, Y.; Geiger, T.L.; Gilfillan, S.; Fuchs, A.; Vivier, E.; Sun, J.C.; et al. Transforming growth factor-β signaling guides the differentiation of innate lymphoid cells in salivary glands. Immunity 2016, 44, 1127–1139. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhao, Q.; Zhang, L.; Hai, B.; Wang, J.; Baetge, C.L.; Deveau, M.A.; Kapler, G.M.; Feng, J.Q.; Liu, F. Transient activation of the hedgehog-gli pathway rescues radiotherapy-induced dry mouth via recovering salivary gland resident macrophages. Cancer Res. 2020, 80, 5531–5542. [Google Scholar] [CrossRef]
- Thom, J.T.; Walton, S.M.; Torti, N.; Oxenius, A. Salivary gland resident APCs are Flt3L- and CCR2-independent macrophage-like cells incapable of cross-presentation. Eur. J. Immunol. 2014, 44, 706–714. [Google Scholar] [CrossRef] [PubMed]
- Ambrosi, A.; Wahren-Herlenius, M. Update on the immunobiology of Sjögren’s syndrome. Curr. Opin. Rheumatol. 2015, 27, 468–475. [Google Scholar] [CrossRef]
- Lessard, C.J.; Li, H.; Adrianto, I.; Ice, J.A.; Rasmussen, A.; Grundahl, K.M.; Kelly, J.A.; Dozmorov, M.G.; Miceli-Richard, C.; Bowman, S.; et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren’s syndrome. Nat. Genet. 2013, 45, 1284–1292. [Google Scholar] [CrossRef]
- Pontarini, E.; Lucchesi, D.; Bombardieri, M. Current views on the pathogenesis of Sjögren’s syndrome. Curr. Opin. Rheumatol. 2018, 30, 215–221. [Google Scholar] [CrossRef] [PubMed]
- Harris, V.M.; Scofield, R.H.; Sivils, K.L. Genetics in Sjögren’s syndrome: Where we are and where we go. Clin. Exp. Rheumatol. 2019, 118, 234–239. [Google Scholar]
- Wei, Y.; Li, N.; Zhao, L.; Yang, C.; Ma, B.; Li, X.; Wei, R.; Nian, H. MicroRNAs and autoimmune-mediated eye diseases. Front. Cell Dev. Biol. 2020, 8, 818. [Google Scholar] [CrossRef]
- Sullivan, D.A.; Rocha, E.M.; Aragona, P.; Clayton, J.A.; Ding, J.; Golebiowski, B.; Hampel, U.; McDermott, A.M.; Schaumberg, D.A.; Srinivasan, S.; et al. TFOS DEWS II sex, gender, and hormones report. Ocul. Surf. 2017, 15, 284–333. [Google Scholar] [CrossRef]
- Brandt, J.E.; Priori, R.; Valesini, G.; Fairweather, D. Sex differences in Sjogren’s syndrome: A comprehensive review of immune mechanisms. Biol. Sex Differ. 2015, 6, 19. [Google Scholar] [CrossRef]
- Schwenkhagen, A. Hormonal changes in menopause and implications on sexual health. J. Sex Med. 2007, 4, 220–226. [Google Scholar] [CrossRef] [PubMed]
- Luu-The, V.; Labrie, F. The intracrine sex steroid biosynthesis pathways. Prog. Brain Res. 2010, 181, 177–192. [Google Scholar] [PubMed]
- Labrie, F. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause. J. Steroid Biochem. Mol. Biol. 2015, 145, 133–138. [Google Scholar] [CrossRef]
- Valtysdóttir, S.T.; Wide, L.; Hällgren, R. Low serum dehydroepiandrosterone sulfate in women with primary Sjögren’s syndrome as an isolated sign of impaired HPA axis function. J. Rheumatol. 2001, 28, 1259–1265. [Google Scholar]
- Sullivan, D.A.; Bélanger, A.; Cermak, J.M.; Bérubé, R.; Papas, A.S.; Sullivan, R.M.; Yamagami, H.; Dana, M.R.; Labrie, F. Are women with Sjögren’s syndrome androgen-deficient? J. Rheumatol. 2003, 30, 2413–2419. [Google Scholar]
- Versura, P.; Giannaccare, G.; Campos, E.C. Sex-steroid imbalance in females and dry eye. Curr. Eye Res. 2015, 40, 162–175. [Google Scholar] [CrossRef]
- Morthen, M.K.; Tellefsen, S.; Richards, S.M.; Lieberman, S.M.; Rahimi Darabad, R.; Kam, W.R.; Sullivan, D.A. Testosterone influence on gene expression in lacrimal glands of mouse models of Sjögren syndrome. Invest. Ophthalmol. Vis. Sci. 2019, 60, 2181–2197. [Google Scholar] [CrossRef] [PubMed]
- Porola, P.; Laine, M.; Virkki, L.; Poduval, P.; Konttinen, Y.T. The influence of sex steroids on Sjögren’s syndrome. Ann. NY Acad. Sci. 2007, 1108, 426–432. [Google Scholar] [CrossRef] [PubMed]
- Klein, S.L.; Flanagan, K.L. Sex differences in immune responses. Nat. Rev. Immunol. 2016, 16, 626–638. [Google Scholar] [CrossRef] [PubMed]
- Berghofer, B.; Frommer, T.; Haley, G.; Fink, L.; Bein, G.; Hackstein, H. TLR7 ligands induce higher IFN-α production in females. J. Immunol. 2006, 177, 2088–2096. [Google Scholar] [CrossRef] [Green Version]
- Weinstein, Y.; Ran, S.; Segal, S. Sex-associated differences in the regulation of immune responses controlled by the MHC of the mouse. J. Immunol. 1984, 132, 656–661. [Google Scholar]
- Russi, A.E.; Walker-Caulfield, M.E.; Ebel, M.E.; Brown, M.A. Cutting edge: C-kit signaling differentially regulates type 2 innate lymphoid cell accumulation and susceptibility to central nervous system demyelination in male and female SJL mice. J. Immunol. 2015, 194, 5609–5613. [Google Scholar] [CrossRef] [Green Version]
- Uppal, S.S.; Verma, S.; Dhot, P.S. Normal values of CD4 and CD8 lymphocyte subsets in healthy Indian adults and the effects of sex, age, ethnicity, and smoking. Cytometry B Clin. Cytom. 2003, 52, 32–36. [Google Scholar] [CrossRef]
- Straub, R.H. The complex role of estrogens in inflammation. Endocr. Rev. 2007, 28, 521–574. [Google Scholar]
- D’Agostino, P.; Milano, S.; Barbera, C.; Di Bella, G.; La Rosa, M.; Ferlazzo, V.; Farruggio, R.; Miceli, D.M.; Miele, M.; Castagnetta, L.; et al. Sex hormones modulate inflammatory mediators produced by macrophages. Ann. NY Acad. Sci. 1999, 876, 426–429. [Google Scholar] [CrossRef]
- Liva, S.M.; Voskuhl, R.R. Testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production. J. Immunol. 2001, 167, 2060–2067. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Foulks, G.N.; Forstot, S.L.; Donshik, P.C.; Forstot, J.Z.; Goldstein, M.H.; Lemp, M.A.; Nelson, J.D.; Nichols, K.K.; Pflugfelder, S.C.; Tanzer, J.M.; et al. Clinical guidelines for management of dry eye associated with Sjögren disease. Ocul. Surf. 2015, 13, 118–132. [Google Scholar] [CrossRef]
- Moutsopoulos, H.M. Sjogren’s syndrome: A forty-year scientific journey. J. Autoimmun. 2014, 51, 1e9. [Google Scholar] [CrossRef]
- Tabbara, K.F.; Ohashi, Y. Lacrimal gland autoimmunity in New Zealand mice. Int. Ophthalmol. Clin. 1985, 25, 153–163. [Google Scholar] [CrossRef] [PubMed]
- Christodoulou, M.I.; Kapsogeorgou, E.K.; Moutsopoulos, H.M. Characteristics of the minor salivary gland infiltrates in Sjogren’s syndrome. J. Autoimmun. 2010, 34, 400e7. [Google Scholar] [CrossRef] [PubMed]
- Sullivan, D.A. Possible mechanisms involved in the reduced tear secretion in Sjoogren’s syndrome. In Sjoogren’s Syndrome State of the Art; Homma, M., Sugai, S., Tojo, T., Miyasaka, N., Akizuki, M., Eds.; Kugler Press: Amsterdam, The Netherlands, 1994; p. 3e19. [Google Scholar]
- Xu, K.P.; Katagiri, S.; Takeuchi, T.; Tsubota, K. Biopsy of labial salivary glands and lacrimal glands in the diagnosis of Sjogren’s syndrome. J. Rheumatol. 1996, 23, 76e82. [Google Scholar]
- Alpert, S.; Kang, H.I.; Weissman, I.; Fox, R.I. Expression of granzyme A in salivary gland biopsies from patients with primary Sjogren’s syndrome. Arthritis Rheum. 1994, 37, 1046e54. [Google Scholar] [CrossRef]
- Tsubota, K.; Saito, I.; Miyasaka, N. Granzyme A and perforin expressed in the lacrimal glands of patients with Sjogren’s syndrome. Am. J. Ophthalmol. 1994, 117, 120e1. [Google Scholar] [CrossRef]
- Tsubota, K.; Xu, K.P.; Fujihara, T.; Katagiri, S.; Takeuchi, T. Decreased reflex tearing is associated with lymphocytic infiltration in lacrimal glands. J. Rheumatol. 1996, 23, 313e20. [Google Scholar]
- Xuan, J.; Shen, L.; Malyavantham, K.; Pankewycz, O.; Ambrus, J.L., Jr.; Suresh, L. Temporal histological changes in lacrimal and major salivary glands in mouse models of Sjogren’s syndrome. BMC Oral Health 2013, 13, 51. [Google Scholar] [CrossRef] [Green Version]
- Jonsson, M.V.; Skarstein, K.; Jonsson, R.; Brun, J.G. Serological implications of germinal center-like structures in primary Sjogren’s syndrome. J Rheumatol. 2007, 34, 2044–2049. [Google Scholar] [PubMed]
- Skopouli, F.N.; Li, L.; Boumba, D.; Stefanaki, S.; Hanel, K.; Moutsopoulos, H.M.; Krilis, S.A. Association of mast cells with fibrosis and fatty infiltration in the minor salivary glands of patients with Sjogren’s syndrome. Clin. Exp. Rheumatol. 1998, 16, 63–65. [Google Scholar] [PubMed]
- Contreras-Ruiz, L.; Regenfuss, B.; Mir, F.A.; Kearns, J.; Masli, S. Conjunctival inflammation in thrombospondin-1 deficient mouse model of Sjögren’s syndrome. PLoS ONE 2013, 8, e75937. [Google Scholar] [CrossRef] [PubMed]
- Meng, Z.; Klinngam, W.; Edman, M.C.; Hamm-Alvarez, S.F. Interferon-γ treatment in vitro elicits some of the changes in cathepsin S and antigen presentation characteristic of lacrimal glands and corneas from the NOD mouse model of Sjögren’s Syndrome. PLoS ONE 2017, 12, e0184781. [Google Scholar] [CrossRef] [Green Version]
- Bianciardi, G.; Latronico, M.E.; Traversi, C. Entropy of corneal nerve fibers distribution observed by laser scanning confocal microscopy: A noninvasive quantitative method to characterize the corneal innervation in Sjogren’s syndrome patients. Microsc. Res. Tech. 2015, 78, 1069–1074. [Google Scholar] [CrossRef] [PubMed]
- Villani, E.; Galimberti, D.; Viola, F.; Mapelli, C.; Ratiglia, R. The cornea in Sjogren’s syndrome: An in vivo confocal study. Invest, Ophthalmol. Vis. Sci. 2007, 48, 2017–2022. [Google Scholar] [CrossRef]
- De Paiva, C.S.; Hwang, C.S.; Pitcher, J.D., 3rd; Pangelinan, S.B.; Rahimy, E.; Chen, W.; Yoon, K.C.; Farley, W.J.; Niederkorn, J.Y.; Stern, M.E.; et al. Age-related T-cell cytokine profile parallels corneal disease severity in Sjogren’s syndrome-like keratoconjunctivitis sicca in CD25KO mice. Rheumatology 2010, 49, 246–258. [Google Scholar] [CrossRef] [Green Version]
- Turpie, B.; Yoshimura, T.; Gulati, A.; Rios, J.D.; Dartt, D.A.; Masli, S. Sjogren’s syndrome-like ocular surface disease in thrombospondin-1 deficient mice. Am. J. Pathol. 2009, 175, 1136–1147. [Google Scholar] [CrossRef] [Green Version]
- You, I.C.; Bian, F.; Volpe, E.S.; de Paiva, C.S.; Pflugfelder, S.C. Age-related conjunctival disease in the C57BL/6.nodaec1aec2 mouse model of Sjogren syndrome develops independent of lacrimal dysfunction. Investig. Ophthalmol. Vis. Sci. 2015, 56, 2224–2233. [Google Scholar] [CrossRef] [Green Version]
- Stern, M.E.; Gao, J.; Schwalb, T.A.; Ngo, M.; Tieu, D.D.; Chan, C.C.; Reis, B.L.; Whitcup, S.M.; Thompson, D.; Smith, J.A. Conjunctival T-cell subpopulations in Sjogren’s and non-Sjogren’s patients with dry eye. Investig. Ophthalmol. Vis. Sci. 2002, 43, 2609e14. [Google Scholar]
- Knop, E.; Knop, N. Eye-associated lymphoid tissue (EALT) is continuously spread throughout the ocular surface from the lacrimal gland to the lacrima drainage system. Der Ophthalmologe Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 2003, 100, 929e42. [Google Scholar]
- Gao, J.; Schwalb, T.A.; Addeo, J.V.; Ghosn, C.R.; Stern, M.E. The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: The effect of topical Cyclosporin A therapy. Cornea 1998, 17, 654e63. [Google Scholar] [CrossRef] [PubMed]
- Croft, M.; Dubey, C. Accessory molecule and costimulation requirements for CD4 T cell response. Crit. Rev. Immunol. 1997, 17, 89e118. [Google Scholar] [CrossRef] [PubMed]
- Caffery, B.E.; Joyce, E.; Heynen, M.L.; Ritter, R., 3rd; Jones, L.A.; Senchyna, M. Quantification of conjunctival TNF-α in aqueous-deficient dry eye. Optom. Vis. Sci. 2014, 91, 156–162. [Google Scholar] [CrossRef] [PubMed]
- Li, S.; Gallup, M.; Chen, Y.T.; McNamara, N.A. Molecular mechanism of proinflammatory cytokine-mediated squamous metaplasia in human corneal epithelial cells. Investig. Ophthalmol. Vis. Sci. 2010, 51, 2466–2475. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pflugfelder, S.C.; Corrales, R.M.; Moore, Q.L.; Volpe, E.A.; Gumus, K.; Zaheer, M.; De Paiva, C.S. Markers of squamous metaplasia in tear dysfunction correlate with conjunctival interferon- gamma expression. Investig. Ophthalmol. Vis. Sci. 2014, 55, 2003. [Google Scholar]
- Pflugfelder, S.C.; Jones, D.; Ji, Z.; Afonso, A.; Monroy, D. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren’s syndrome keratocunjunctivitis sicca. Curr. Eye Res. 1999, 19, 201–211. [Google Scholar] [CrossRef]
- Aragona, P.; Aguennouz, M.; Rania, L.; Postorino, E.; Sommario, M.S.; Roszkowska, A.M.; De Pasquale, M.G.; Pisani, A.; Puzzolo, D. Matrix metalloproteinase 9 and transglutaminase 2 expression at the ocular surface in patients with different forms of dry eye disease. Ophthalmology 2015, 122, 62–71. [Google Scholar] [CrossRef]
- Barbosa, F.L.; Xiao, Y.; Bian, F.; Coursey, T.G.; Ko, B.Y.; Clevers, H.; de Paiva, C.S.; Pflugfelder, S.C. Goblet cells contribute to ocular surface immune tolerance-implications for dry eye disease. Int. J. Mol. Sci. 2017, 18, 978. [Google Scholar] [CrossRef] [Green Version]
- De Paiva, C.S.; Villarreal, A.L.; Corrales, R.M.; Rahman, H.T.; Chang, V.Y.; Farley, W.J.; Stern, M.E.; Niederkorn, J.Y.; Li, D.Q.; Pflugfelder, S.C. Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-γ. Investig. Ophthalmol. Vis. Sci. 2007, 48, 2553e60. [Google Scholar] [CrossRef]
- Chen, Y.T.; Nikulina, K.; Lazarev, S.; Bahrami, A.F.; Noble, L.B.; Gallup, M.; McNamara, N.A. Interleukin-1 as a phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sjogren’s syndrome. Am. J. Pathol. 2010, 177, 1333e43. [Google Scholar] [CrossRef] [PubMed]
- Zhang, X.; Chen, W.; De Paiva, C.S.; Corrales, R.M.; Volpe, E.A.; McClellan, A.J.; Farley, W.J.; Li, D.-Q.; Pflugfelder, S.C. Interferon-γ exacerbates dry eye-induced apoptosis in conjunctiva through dual apoptotic pathways. Investig. Ophthalmol. Vis. Sci. 2011, 52, 6279e85. [Google Scholar] [CrossRef]
- Pflugfelder, S.C.; Bian, F.; Gumus, K.; Farley, W.; Stern, M.E.; De Paiva, C.S. Severity of Sjögren’s syndrome keratoconjunctivitis sicca increases with increased percentage of conjunctival antigen-presenting cells. Int. J. Mol. Sci. 2018, 19, 2760. [Google Scholar] [CrossRef] [Green Version]
- Lee, O.L.; Tepelus, T.C.; Huang, J.; Irvine, A.G.; Irvine, C.; Chiu, G.B.; Sadda, S.R. Evaluation of the corneal epithelium in non-Sjögren’s and Sjögren’s dry eyes: An in vivo confocal microscopy study using HRT III RCM. BMC Ophthalmol. 2018, 18, 309. [Google Scholar] [CrossRef] [PubMed]
- Wakamatsu, T.H.; Sato, E.A.; Matsumoto, Y.; Ibrahim, O.M.A.; Dogru, M.; Kaido, M.; Ishida, R.; Tsubota, K. Conjunctival in vivo confocal scanning laser microscopy in patients with Sjögren’s syndrome. Investig. Ophthalmol. Vis. Sci. 2010, 51, 144–150. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Benitez del Castillo, J.M.; Wasfy, M.A.S.; Fernandez, C.; Garcia-Sanchez, J. An in vivo confocal masked study on corneal epithelium and subbasal nerves in patients with dry eye. Investig. Ophthalmol. Vis. Sci. 2004, 45, 3030–3035. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Benitez del Castillo, J.M.; Acosta, M.C.; Wassfi, M.A.; Diaz-Valle, D.; Gegundez, J.A.; Fernandez, C.; Garcia-Sanchez, J. Relation between corneal innervation with confocal microscopy and corneal sensitivity with noncontact esthesiometry in patients with dry eye. Investig. Ophthalmol. Vis. Sci. 2007, 48, 173–181. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Matsumoto, Y.; Ibrahim, O.M.A.; Kojima, T.; Dogru, M.; Shimazaki, J.; Tsubota, K. Corneal in vivo laser-scanning confocal microscopy findings in dry eye patients with Sjögren’s syndrome. Diagnostics 2020, 10, 497. [Google Scholar] [CrossRef]
- Sullivan, D.A.; Dana, R.; Sullivan, R.M.; Krenzer, K.L.; Sahin, A.; Arica, B.; Liu, Y.; Kam, W.R.; Papas, A.S.; Cermak, J.M. Meibomian gland dysfunction in primary and secondary Sjögren syndrome. Ophthalmic. Res. 2018, 59, 193–205. [Google Scholar] [CrossRef]
- Kang, Y.S.; Lee, H.S.; Li, Y.; Choi, W.; Yoon, K.C. Manifestation of meibomian gland dysfunction in patients with Sjögren’s syndrome, non-Sjögren’s dry eye, and non-dry eye controls. Int. Ophthalmol. 2018, 38, 1161–1167. [Google Scholar] [CrossRef]
- Menzies, K.L.; Srinivasan, S.; Prokopich, C.L.; Jones, L. Infrared imaging of meibomian glands and evaluation of the lipid layer in Sjögren’s syndrome patients and nondry eye controls. Investig. Ophthalmol. Vis. Sci. 2015, 56, 836–841. [Google Scholar] [CrossRef] [Green Version]
- Zhao, J.; Manthorpe, R.; Wollmer, P. Surface activity of tear fluid in patients with primary Sjögren’s syndrome. Clin. Physiol. Funct. Imaging 2002, 22, 24–27. [Google Scholar] [CrossRef] [Green Version]
- Goto, E.; Matsumoto, Y.; Kamoi, M.; Endo, K.; Ishida, R.; Dogru, M.; Kaido, M.; Kojima, T.; Tsubota, K. Tear evaporation rates in Sjogren syndrome and non-Sjogren dry eye patients. Am. J. Ophthalmol. 2007, 144, 81–85. [Google Scholar] [CrossRef] [PubMed]
- Zang, S.; Cui, Y.; Cui, Y.; Fei, W. Meibomian gland dropout in Sjögren’s syndrome and non-Sjögren’s dry eye patients. Eye 2018, 32, 1681–1687. [Google Scholar] [CrossRef]
- Tong, L.; Beuerman, R.; Simonyi, S.; Hollander, D.A.; Stern, M.E. Effects of punctal occlusion on clinical signs and symptoms and on tear cytokine levels in patients with dry eye. Ocul. Surf. 2016, 14, 233–241. [Google Scholar] [CrossRef] [Green Version]
- Pucker, A.D.; Ng, S.M.; Nichols, J.J. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database Syst. Rev. 2016, 2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aragona, P.; Papa, V.; Micali, A.; Santocono, M.; Milazzo, G. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br. J. Ophthalmol. 2002, 86, 181–184. [Google Scholar] [CrossRef] [PubMed]
- Brignole, F.; Pisella, P.J.; Dupas, B.; Baeyens, V.; Baudouin, C. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefes Arch. Clin. Exp. Ophthalmol. 2005, 243, 531–538. [Google Scholar] [CrossRef]
- Condon, P.I.; McEwen, C.G.; Wright, M.; Mackintosh, G.; Prescott, R.J.; McDonald, C. Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome. Br. J. Ophthalmol. 1999, 83, 1121–1124. [Google Scholar] [CrossRef] [Green Version]
- McDonald, C.C.; Kaye, S.B.; Figueiredo, F.C.; Macintosh, G.; Lockett, C.A. Randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye 2002, 16, 601–607. [Google Scholar] [CrossRef] [Green Version]
- Aragona, P.; Di Stefano, G.; Ferreri, F.; Spinella, R.; Stilo, A. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren’s syndrome patients. Br. J. Ophthalmol. 2002, 86, 879–884. [Google Scholar] [CrossRef] [Green Version]
- Aragona, P.; Rania, L.; Roszkowska, A.M.; Spinella, R.; Postorino, E.; Puzzolo, D.; Micali, A. Effects of amino acids enriched tears substitutes on the cornea of patients with dysfunctional tear syndrome. Acta Ophthalmologica 2013, 91, e437–e444. [Google Scholar] [CrossRef] [PubMed]
- Guidera, A.C.; Luchs, J.I.; Udell, I.J. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology 2001, 108, 936–944. [Google Scholar] [CrossRef]
- Aragona, P.; Stilo, A.; Ferreri, F.; Mobrici, M. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjögren’s syndrome patients. Eye 2005, 19, 535–539. [Google Scholar] [CrossRef] [Green Version]
- Marsh, P.; Pflugfelder, S.C. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology 1999, 106, 811–816. [Google Scholar] [CrossRef]
- Lin, T.; Gong, L. Topical fluorometholone treatment for ocular dryness in patients with Sjögren syndrome. Medicine 2015, 94, e551. [Google Scholar] [CrossRef]
- Gündüz, K.; Ozdemir, O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren’s syndrome. Acta Ophthalmologica 1994, 72, 438–442. [Google Scholar] [CrossRef]
- Stevenson, D.; Tauber, J.; Reis, B.L.; The Cyclosporin A Phase 2 Study Group. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: A dose-ranging, randomized trial. Ophthalmology 2000, 107, 967–974. [Google Scholar] [CrossRef]
- Toker, E.; Asfuroğlu, E. Corneal and conjunctival sensitivity in patients with dry eye: The effect of topical cyclosporine therapy. Cornea 2010, 29, 133–140. [Google Scholar] [CrossRef]
- Perry, H.D.; Solomon, R.; Donnenfeld, E.D.; Perry, A.R.; Wittpenn, J.R.; Greenman, H.E.; Savage, H.E. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch. Ophthalmol. 2008, 126, 1046–1050. [Google Scholar] [CrossRef] [Green Version]
- Sall, K.; Stevenson, O.D.; Mundorf, T.K.; Reis, B.L.; CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 2000, 107, 631–639. [Google Scholar] [CrossRef]
- Barber, L.D.; Pflugfelder, S.C.; Tauber, J.; Foulks, G.N. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 2005, 112, 1790–1794. [Google Scholar] [CrossRef]
- Fan, W.S.; Hung, H.L.; Liao, H.P.; Lai, N.S. Topical cyclosporine therapy for keratoconjunctivitis sicca in Sjögren’s syndrome. Tzu Chi Med. J. 2003, 15, 85–89. [Google Scholar]
- Pan, Q.; Angelina, A.; Marrone, M.; Stark, W.J.; Akpek, E.K. Autologous serum eye drops for dry eye. Cochrane Database Syst. Rev. 2017, 252. [Google Scholar] [CrossRef] [PubMed]
- Noble, B.A.; Loh, R.S.; MacLennan, S.; Pesudovs, K.; Reynolds, A.; Bridges, L.R.; Burr, J. O Stewart,1 and S Quereshi1. Comparison of autologous serum eye drops with conventional therapy in a randomized controlled crossover trial for ocular surface disease. Br. J. Ophthalmol. 2004, 88, 647–652. [Google Scholar] [CrossRef]
- Alio, J.L.; Rodriguez, A.E.; WróbelDudzińska, D. Eye platelet-rich plasma in the treatment of ocular surface disorders. Curr. Opin. Ophthalmol. 2015, 26, 325–332. [Google Scholar] [CrossRef] [PubMed]
- Soni, N.G.; Jeng, B.H. Blood-derived topical therapy for ocular surface diseases. Br. J. Ophthalmol. 2016, 100, 22–27. [Google Scholar] [CrossRef]
- Joe, A.W.; Gregory-Evans, K. Mesenchymal stem cells and potential applications in treating ocular disease. Curr. Eye Res. 2010, 35, 941–952. [Google Scholar] [CrossRef]
- Zhang, L.; Coulson-Thomas, V.J.; Ferreira, T.G.; Kao, W.W.Y. Mesenchymal stem cells for treating ocular surface diseases. BMC Ophthalmol. 2015, 15, 155. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dhamodaran, K.; Subramani, M.; Ponnalagu, M.; Shetty, R.; Das, D. Ocular stem cells: A status update! Stem Cell Res. Ther. 2014, 5, 56. [Google Scholar] [CrossRef] [Green Version]
- Sivan, P.P.; Syed, S.; Mok, P.-L.; Higuchi, A.; Murugan, K.; Alarfaj, A.A.; Munusamy, M.A.; Awang Hamat, R.; Umezawa, A.; Kumar, S. Stem cell therapy for treatment of ocular disorders. Stem Cells Int. 2016, 2016, 8304879. [Google Scholar] [CrossRef]
- Yao, L.; Bai, H. Review: Mesenchymal stem cells and corneal reconstruction. Mol. Vis. 2013, 19, 2237–2243. [Google Scholar]
- Lee, M.J.; Ko, A.Y.; Ko, J.H.; Lee, H.J.; Kim, M.K.; Wee, W.R.; Khwarg, S.I.; Oh, J.Y. Mesenchymal stem/stromal cells protect the ocular surface by suppressing inflammation in an experimental dry eye. Mol. Ther. 2015, 23, 139–146. [Google Scholar] [CrossRef] [Green Version]
- Ljubimov, A.V.; Saghizadeh, M. Progress in corneal wound healing. Prog. Retin. Eye Res. 2015, 49, 17–45. [Google Scholar] [CrossRef] [Green Version]
- Aluri, H.S.; Samizadeh, M.; Edman, M.C.; Hawley, D.R.; Armaos, H.L.; Janga, S.R.; Meng, Z.; Sendra, V.G.; Hamrah, P.; Kublin, C.L.; et al. Delivery of bone marrow-derived mesenchymal stem cells improves tear production in a mouse model of Sjögren’s syndrome. Stem Cells Int. 2017, 2017, 3134543. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Beyazyıldız, E.; Pınarlı, F.A.; Beyazyıldız, O.; Hekimoğlu, E.R.; Acar, U.; Demir, M.N.; Albayrak, A.; Kaymaz, F.; Sobacı, G.; Delibaşı, T. Efficacy of topical mesenchymal stem cell therapy in the treatment of experimental dry eye syndrome model. Stem Cells Int. 2014, 2014, 250230. [Google Scholar] [CrossRef]
- Villatoro, A.J.; Fernández, V.; Claros, S.; Rico-Llanos, G.A.; Becerra, J.; Andrades, J.A. Use of adipose-derived mesenchymal stem cells in keratoconjunctivitis sicca in a canine model. Biomed. Res. Int. 2015, 2015, 527926. [Google Scholar] [CrossRef]
- Vivino, F.B.; Al-Hashimi, I.; Khan, Z.; LeVeque, F.G.; Salisbury, P.L., 3rd; Tran-Johnson, T.K.; Muscoplat, C.C.; Trivedi, M.; Goldlust, B.; Gallagher, S.C. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: A randomized, placebo-controlled, fixed-dose, multicenter trial. Arch. Intern. Med. 1999, 159, 174–181. [Google Scholar] [CrossRef] [PubMed]
- Papas, A.S.; Sherrer, Y.S.; Charney, M.; Golden, H.E.; Medsger, T.A., Jr.; Walsh, B.T.; Trivedi, M.; Goldlust, B.; Gallagher, S.C. Successful treatment of dry mouth and dry eye symptoms in Sjögren’s syndrome patients with oral pilocarpine: A randomized, placebocontrolled, dose-adjustment study. J. Clin. Rheumatol. 2004, 10, 169–177. [Google Scholar] [CrossRef]
- Tsifetaki, N.; Kitsos, G.; Paschides, C.A.; Alamanos, Y.; Eftaxias, V.; Voulgari, P.V.; Psilas, K.; Drosos, A.A. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren’s syndrome: A randomised 12 week controlled study. Ann. Rheum. Dis. 2003, 62, 1204–1207. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Petrone, D.; Condemi, J.J.; Fife, R.; Gluck, O.; Cohen, S.; Dalgin, P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren’s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 2002, 46, 748–754. [Google Scholar] [CrossRef]
- Aragona, P.; Di Pietro, R.; Spinella, R.; Mobrici, M. Conjunctival epithelium improvement after systemic pilocarpine in patients with Sjogren’s syndrome. Br. J. Ophthalmol. 2006, 90, 166–170. [Google Scholar] [CrossRef] [PubMed]
- Leung, K.C.; McMillan, A.S.; Wong, M.C.; Leung, W.K.; Mok, M.Y.; Lau, C.S. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren’s syndrome in southern Chinese patients: A randomized double-blind, placebo-controlled crossover study. Clin Rheumatol. 2008, 27, 429–436. [Google Scholar] [CrossRef] [PubMed]
- Fife, R.S.; Chase, W.F.; Dore, R.K.; Wiesenhutter, C.W.; Lockhart, P.B.; Tindall, E.; Sue, J.Y. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: A randomized trial. Arch. Intern. Med. 2002, 162, 1293–1300. [Google Scholar] [CrossRef]
- Ono, M.; Takamura, E.; Shinozaki, K.; Tsumura, T.; Hamano, T.; Yagi, Y.; Tsubota, K. Therapeutic effect of cevimeline on dry eye in patients with Sjögren’s syndrome: A randomized, double-blind clinical study. Am. J. Ophthalmol. 2004, 138, 6–17. [Google Scholar] [CrossRef]
- Meijer, J.M.; Meiners, P.M.; Vissink, A.; Spijkervet, F.K.; Abdulahad, W.; Kamminga, N.; Brouwer, E.; Kallenberg, C.G.; Bootsma, H. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010, 62, 960–968. [Google Scholar] [CrossRef]
- Pijpe, J.; van Imhoff, G.W.; Spijkervet, F.K.; Roodenburg, J.L.; Wolbink, G.J.; Mansour, K.; Vissink, A.; Kallenberg, C.G.; Bootsma, H. Rituximab treatment in patients with primary Sjögren’s syndrome: An open-label phase II study. Arthritis Rheum. 2005, 52, 2740–2750. [Google Scholar] [CrossRef]
- Devauchelle-Pensec, V.; Pennec, Y.; Morvan, J.; Pers, J.O.; Daridon, C.; Jousse-Joulin, S.; Roudaut, A.; Jamin, C.; Renaudineau, Y.; Roué, I.Q.; et al. Improvement of Sjögren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007, 57, 310–317. [Google Scholar] [CrossRef]
- Kruize, A.A.; Hené, R.J.; Kallenberg, C.G.; van Bijsterveld, O.P.; van der Heide, A.; Kater, L.; Bijlsma, J.W. Hydroxychloroquine treatment for primary Sjögren’s syndrome: A two year double blind crossover trial. Ann. Rheum. Dis. 1993, 52, 360–364. [Google Scholar] [CrossRef] [Green Version]
- Yavuz, S.; Asfurog˘lu, E.; Bicakcigil, M.; Toker, E. Hydroxychloroquine improves dry eye symptoms of patients with primary Sjögren’s syndrome. Rheumatol. Int. 2011, 31, 1045–1049. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Roszkowska, A.M.; Oliverio, G.W.; Aragona, E.; Inferrera, L.; Severo, A.A.; Alessandrello, F.; Spinella, R.; Postorino, E.I.; Aragona, P. Ophthalmologic Manifestations of Primary Sjögren’s Syndrome. Genes 2021, 12, 365. https://doi.org/10.3390/genes12030365
Roszkowska AM, Oliverio GW, Aragona E, Inferrera L, Severo AA, Alessandrello F, Spinella R, Postorino EI, Aragona P. Ophthalmologic Manifestations of Primary Sjögren’s Syndrome. Genes. 2021; 12(3):365. https://doi.org/10.3390/genes12030365
Chicago/Turabian StyleRoszkowska, Anna Maria, Giovanni William Oliverio, Emanuela Aragona, Leandro Inferrera, Alice Antonella Severo, Federica Alessandrello, Rosaria Spinella, Elisa Imelde Postorino, and Pasquale Aragona. 2021. "Ophthalmologic Manifestations of Primary Sjögren’s Syndrome" Genes 12, no. 3: 365. https://doi.org/10.3390/genes12030365